← Leaderboards
Paul K Paik
Sloan-Kettering Inst Can Research
$900,783
Attributed
$1,801,566
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $628.6K · FY2021–23$1M$750K$500K$250K$0
'21
'22
'23
Funding mix
By agency
NIH$1,801,566 · 1
By mechanism
R01$1,801,566 · 1
Top collaborators
- Jonathan W Riess3 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Sriram Venneti$4,778,176
- Craig B Thompson$56,520,903
- Johanna Joyce$4,431,412
- Aimee Marie Crago$2,751,471
- Cristina R Antonescu$10,810,455
Others in their field
Other Emerging Leaders on “Frap1 Gene”
- J. Silvio Gutkind · University Of California, San Diego$6,899,246
- Adam R Konopka · University Of Wisconsin-Madison$5,158,185
- David C Fajgenbaum · University Of Pennsylvania$4,678,755
- Daniel R Wahl · University Of Michigan At Ann Arbor$3,904,048
- Jenna L Jewell · Ut Southwestern Medical Center$3,640,006
- Elizabeth Marjorie Cespedes Feliciano · Columbia University Health Sciences$3,499,403
Research focus
Frap1 GeneGenerationsFluorodeoxyglucoseAffectBiopsyBloodBinding SitesExhibitsCancer PatientCellsCheckpoint InhibitionChemotherapyCitric Acid CycleClinical DataCohortCombinatorialContractsEfficacy TestingDependenceDoseDruggable TargetDrug KineticsEffective TherapyGenotype
Grant awards (3)
A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients$581,481
R01 · FY2023 · CA · contact PI
A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients$591,444
R01 · FY2022 · CA · contact PI
A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients$628,641
R01 · FY2021 · CA · contact PI